NCT03566940View on ClinicalTrials.gov

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

PHASE2CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

August 7, 2019

Study Completion Date

October 17, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

sIPV

Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.

BIOLOGICAL

cIPV

Participants will receive 0.5 mL of cIPV as a suspension for IM injection.

Trial Locations (3)

1000

Philippine General Hospital, Manila

4114

De La Salle Health Sciences Institute- DLSUMC, Dasmariñas

De La Salle University Medical Center, Dasmariñas

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03566940 - A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule | Biotech Hunter | Biotech Hunter